A Defective Viral Particle Approach to COVID-19

Cells. 2022 Jan 17;11(2):302. doi: 10.3390/cells11020302.

Abstract

The novel coronavirus SARS-CoV-2 has caused a pandemic resulting in millions of deaths worldwide. While multiple vaccines have been developed, insufficient vaccination combined with adaptive mutations create uncertainty for the future. Here, we discuss novel strategies to control COVID-19 relying on Defective Interfering Particles (DIPs) and related particles that arise naturally during an infection. Our intention is to encourage and to provide the basis for the implementation of such strategies by multi-disciplinary teams. We therefore provide an overview of SARS-CoV-2 for a multi-disciplinary readership that is specifically tailored to these strategies, we identify potential targets based on the current knowledge of the properties and functions of coronaviruses, and we propose specific strategies to engineer DIPs and other interfering or therapeutic nanoparticles.

Keywords: COVID-19; antivirus; aptamer; coronavirus; defective interfering particle; extracellular vesicle; immunity; synthetic defective viral genome; therapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • COVID-19* / epidemiology
  • COVID-19* / metabolism
  • COVID-19* / therapy
  • Defective Interfering Viruses*
  • Humans
  • Nanoparticles / therapeutic use*
  • Pandemics*
  • SARS-CoV-2 / metabolism*